Shinichi Tamu­ra re­claims the throne at So­sei; Jeff Abbey ex­its Ar­gos for No­vadip; Frank Cz­er­wiec is the new CMO at Goldfinch

Jeff Abbey is jump­ing to the helm of Bel­gium’s No­vadip Bio­sciences af­ter lead­ing Ar­gos Ther­a­peu­tics as pres­i­dent and CEO for the past eight years. Hav­ing led No­vadip’s au­tol­o­gous cell ther­a­py through a Phase I/IIa tri­al in spinal fu­sion pa­tients, found­ing CEO Jean-François Pol­let de­cid­ed it’s time to pass the reins to a more ex­pe­ri­enced chief ex­ec­u­tive. And Abbey — whose ex­pe­ri­ence in­cludes over­see­ing a Phase III tri­al, rais­ing over $250 mil­lion in pri­vate fi­nanc­ings and an IPO, and seal­ing sev­er­al part­ner­ships — fits the bill.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.